Literature DB >> 22080479

STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.

Thomas G P Grunewald1, Isabel Diebold, Irene Esposito, Stephanie Plehm, Kristina Hauer, Uwe Thiel, Patricia da Silva-Buttkus, Frauke Neff, Rebekka Unland, Carsten Müller-Tidow, Colette Zobywalski, Katharina Lohrig, Urs Lewandrowski, Albert Sickmann, Olivia Prazeres da Costa, Agnes Görlach, Andrea Cossarizza, Elke Butt, Günther H S Richter, Stefan Burdach.   

Abstract

Ewing tumors comprise the second most common type of bone-associated cancer in children and are characterized by oncogenic EWS/FLI1 fusion proteins and early metastasis. Compelling evidence suggests that elevated levels of intracellular oxidative stress contribute to enhanced aggressiveness of numerous cancers, possibly including Ewing tumors. Using comprehensive microarray analyses and RNA interference, we identified the six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-a membrane-bound mesenchymal stem cell marker of unknown function-as a highly expressed protein in Ewing tumors compared with benign tissues and show its regulation by EWS/FLI1. In addition, we show that STEAP1 knockdown reduces Ewing tumor proliferation, anchorage-independent colony formation as well as invasion in vitro and decreases growth and metastasis of Ewing tumor xenografts in vivo. Moreover, transcriptome and proteome analyses as well as functional studies revealed that STEAP1 expression correlates with oxidative stress responses and elevated levels of reactive oxygen species that in turn are able to regulate redox-sensitive and proinvasive genes. In synopsis, our data suggest that STEAP1 is associated with the invasive behavior and oxidative stress phenotype of Ewing tumors and point to a hitherto unanticipated oncogenic function of STEAP1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080479     DOI: 10.1158/1541-7786.MCR-11-0524

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  Six-Transmembrane Epithelial Antigen of Prostate 1 (STEAP1) Has a Single b Heme and Is Capable of Reducing Metal Ion Complexes and Oxygen.

Authors:  Kwangsoo Kim; Sharmistha Mitra; Gang Wu; Vladimir Berka; Jinmei Song; Ye Yu; Sebastien Poget; Da-Neng Wang; Ah-Lim Tsai; Ming Zhou
Journal:  Biochemistry       Date:  2016-11-17       Impact factor: 3.162

2.  Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Authors:  David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

3.  Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Authors:  Maria E Gierisch; Franziska Pfistner; Laura A Lopez-Garcia; Lena Harder; Beat W Schäfer; Felix K Niggli
Journal:  J Biol Chem       Date:  2016-11-08       Impact factor: 5.157

Review 4.  [Functional genomics of Ewing sarcoma].

Authors:  T G P Grünewald
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

5.  Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.

Authors:  Inês Margarida Gomes; Sandra Moreira Rocha; Carlos Gaspar; Maria Inês Alvelos; Cecília Reis Santos; Sílvia Socorro; Cláudio Jorge Maia
Journal:  Med Oncol       Date:  2018-02-20       Impact factor: 3.064

6.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

7.  mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.

Authors:  Stacia L Koppenhafer; Kelli L Goss; William W Terry; David J Gordon
Journal:  Mol Cancer Ther       Date:  2018-10-03       Impact factor: 6.261

8.  Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Authors:  Christy L Osgood; Nichole Maloney; Christopher G Kidd; Susan Kitchen-Goosen; Laura Segars; Meti Gebregiorgis; Girma M Woldemichael; Min He; Savita Sankar; Stephen L Lessnick; Min Kang; Malcolm Smith; Lisa Turner; Zachary B Madaj; Mary E Winn; Luz-Elena Núñez; Javier González-Sabín; Lee J Helman; Francisco Morís; Patrick J Grohar
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

Review 9.  STEAP4 and insulin resistance.

Authors:  Xiaoling Chen; Zhiqing Huang; Bo Zhou; Huan Wang; Gang Jia; Guangmang Liu; Hua Zhao
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

Review 10.  Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Authors:  Elizabeth R Lawlor; Poul H Sorensen
Journal:  Crit Rev Oncog       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.